...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress

Poster Two is available here. The treatment period is still ambiguous. BETonMACE study design reads up to 104 weeks treatment. Results reads 6 to 36 months treatment. Nice baseline data on the n=259 CKD sub population.

BETonMACE Chronic Kidney Disease Sub-Study: Effects of the Selective BET-Inhibitor Apabetalone on Kidney Function and MACE in Post-ACS Patients with Diabetes and Estimated Glomerular Filtration Rate Below 60. 

Share
New Message
Please login to post a reply